Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H15F3N4O3.C7H8O3S.H2O |
| Molecular Weight | 594.56 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC=C(C=C1)S(O)(=O)=O.NC2CCN(C2)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=C(F)C=C(F)C=C5)C(O)=O
InChI
InChIKey=SSULTCPIIYRGFQ-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3.C7H8O3S.H2O/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;1-6-2-4-7(5-3-6)11(8,9)10;/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);2-5H,1H3,(H,8,9,10);1H2
| Molecular Formula | C7H8O3S |
| Molecular Weight | 172.202 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H15F3N4O3 |
| Molecular Weight | 404.3426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf
Curator's Comment: description was created based on several sources, including:
http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf
Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311224 |
|||
Target ID: CHEMBL2363076 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1990 |
|||
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1990 |
|||
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1991 |
|||
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1990 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids. | 1992 Feb 7 |
|
| Trovafloxacin is active against Toxoplasma gondii. | 1996 Aug |
|
| N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. | 1996 Nov |
|
| Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. | 1996 Oct |
|
| [In vitro anti-MAC activities of new quinolones in focus (2)]. | 1996 Sep |
|
| Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. | 1999 Oct |
|
| In vitro method for prediction of the phototoxic potentials of fluoroquinolones. | 2001 Dec |
|
| Quinolones alter defense reactions mediated by macrophages. | 2001 Feb |
|
| [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone]. | 2002 Dec |
|
| In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species. | 2002 Mar |
|
| Pharmacokinetics and safety assessment of tosufloxacin tosilate. | 2002 Mar |
|
| [The history of the development and changes of quinolone antibacterial agents]. | 2003 |
|
| [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. | 2003 Feb |
|
| [Salmonella infections]. | 2003 Feb |
|
| Alteration of constitutive apoptosis in neutrophils by quinolones. | 2003 Jun |
|
| Anaphylaxis due to tosufloxacin tosilate. | 2003 Sep |
|
| Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis. | 2004 Apr |
|
| Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. | 2004 Apr |
|
| [Molecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan]. | 2004 May |
|
| Antimicrobial safety: focus on fluoroquinolones. | 2005 Jul 15 |
|
| [Successful treatment with voriconazole for disseminated cutaneous and visceral infection by Fusarium solani in a patient with acute myeloid leukemia]. | 2006 Aug |
|
| [Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. | 2006 Dec |
|
| [Effectiveness of switch therapy for peritonitis]. | 2007 Aug |
|
| [Susceptibility of clinical isolates from primary care clinics to oral antibacterial agents]. | 2007 Feb |
|
| [Sensitivity surveillance of Haemophilus influenzae isolates for several antibiotics in Gifu Prefecture (2006)]. | 2008 Aug |
|
| In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin. | 2008 Mar |
|
| Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. | 2009 Jun 18 |
|
| [Antibiotic susceptibility of blood-borne Streptococcus pneumoniae and efficacy assessment of respiratory quinolones using Monte Carlo simulation]. | 2010 Feb |
Patents
Sample Use Guides
In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Osteomyelitis, arthritis: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 3 times a day. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Typhoid/paratyphoid fever: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 4 times a day for 14 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:36:34 GMT 2023
by
admin
on
Sat Dec 16 04:36:34 GMT 2023
|
| Record UNII |
5L69LG8ZDQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000164913
Created by
admin on Sat Dec 16 04:36:34 GMT 2023 , Edited by admin on Sat Dec 16 04:36:34 GMT 2023
|
PRIMARY | |||
|
SUB179549
Created by
admin on Sat Dec 16 04:36:34 GMT 2023 , Edited by admin on Sat Dec 16 04:36:34 GMT 2023
|
PRIMARY | |||
|
32248
Created by
admin on Sat Dec 16 04:36:34 GMT 2023 , Edited by admin on Sat Dec 16 04:36:34 GMT 2023
|
PRIMARY | |||
|
1400591-39-0
Created by
admin on Sat Dec 16 04:36:34 GMT 2023 , Edited by admin on Sat Dec 16 04:36:34 GMT 2023
|
PRIMARY | |||
|
5282468
Created by
admin on Sat Dec 16 04:36:34 GMT 2023 , Edited by admin on Sat Dec 16 04:36:34 GMT 2023
|
PRIMARY | |||
|
5L69LG8ZDQ
Created by
admin on Sat Dec 16 04:36:34 GMT 2023 , Edited by admin on Sat Dec 16 04:36:34 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |